Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GC 203

Next Previous
Drug Profile

GC 203

Alternative Names: GC-203; GC203 TIL; Membrane bound cytokine modified TIL - Shanghai Juncell Therapeutics; Tumour infiltrating lymphocyte (TIL) engineered with membrane-binding cytokine therapy - Shanghai Juncell Therapeutics

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Juncell Therapeutics
  • Class Antineoplastics; Cell therapies; Cytokines; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Cytokine replacements; Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Gynaecological cancer

Most Recent Events

  • 30 Jan 2026 Shanghai Juncell Therapeutics initiates a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) (IV) (NCT07256756)
  • 30 Nov 2025 Shanghai Juncell Therapeutics plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) (IV), in November 2025 (NCT07256756)
  • 28 Apr 2025 No recent reports of development identified for phase-0 development in Gynaecological-cancer(Late-stage disease) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top